Sponsors (5)
Official title: To strengthen the 340B drug discount program.
Introduced July 6, 2026 by Scott Peters · Last progress July 6, 2026
The bill strengthens 340B program integrity, transparency, and patient protections—likely directing more discounts to intended safety-net uses—at the cost of materially greater reporting, audit, and compliance burdens (and some enforcement, price-shift, and access risks) for providers, pharmacies, manufacturers, and payers.
Taxpayers, Medicare/Medicaid programs, and patients: stronger program integrity through audits, a national clearinghouse, expanded reporting, and enforcement reduces duplicate discounts and drug diversion so 340B benefits more reliably reach safety-net providers and protects federal/state funds.
Low-income, uninsured, and other vulnerable patients: enforceable financial-assistance rules, limits on debt collection, point-of-care notices and non-English summaries increase access to assistance and reduce out-of-pocket costs and credit harm.
Patients and safety-net providers: required near-term manufacturer price reductions and improved claims-data sharing (clearinghouse) help preserve immediate 340B savings and make it easier to identify and resolve duplicate discounts.
Hospitals, clinics, community health centers, and contract pharmacies (especially smaller and rural providers): far higher administrative, reporting, recordkeeping, audit, and compliance costs from new registrations, attestations, data submissions, and frequent audits.
Patients (low-income, Medicaid/Medicare beneficiaries, and those with irregular care): risk of disrupted access or higher out-of-pocket costs if sites lose eligibility, are suspended/disenrolled after audits, or manufacturers suspend discounts for noncompliant entities.
Manufacturers, PBMs, and insurers: mandatory price concessions and new constraints on PBM/TPA practices could prompt manufacturers to shift list prices elsewhere and PBMs/insurers to raise premiums, narrow networks, or change benefit designs, indirectly raising costs for employers, taxpayers, and patients.
Based on analysis of 13 sections of legislative text.
Creates a 340B user-fee, tightens eligibility/oversight for child sites and contract pharmacies, mandates audits/reporting, requires patient financial-assistance and debt protections, and imposes clearinghouse pricing rules for manufacturers.
Creates a new user-fee program for 340B covered entities starting FY2027, strengthens oversight and auditing, and requires new reporting, registration, and eligibility rules for child sites and contract pharmacies. It mandates patient financial-assistance and medical-debt protections for many covered entities, requires manufacturers to provide immediate purchase-price reductions through a validated clearinghouse for a time-limited period, and prohibits discrimination by plans/PBMs against 340B participants. Implements new data collection, public reporting, audits, Comptroller General studies, HHS rulemaking deadlines (many within 180 days), direct-hire authority, and multi-year appropriations for oversight activities. The measure phases some requirements and includes civil monetary penalties for violations and repeated audit requirements for covered entities, child sites, and contract pharmacies.